Background and Aim: This study aimed to identify predictors of model for end-stage liver disease sodium score reductions and improvements in vital prognoses following portosystemic shunt occlusion in portal hypertension patients. Methods: Seventy cirrhotic patients with major portosystemic shunts and a mean model for end-stage liver disease sodium score of 10.5 underwent balloon-occluded retrograde transvenous obliteration between February 2008 and March 2017. We calculated the scores before and 1 month after shunt occlusion. The long-term outcomes were monitored, and vital prognoses were analyzed. Results: The model for end-stage liver disease sodium score did not change significantly 1 month post-balloon-occluded retrograde transvenous obliteration, and the score decreased postoperatively in 31 (44.3%) patients. Univariate analyses showed that decline in the score after portosystemic shunt occlusion was strongly associated with hepatic encephalopathy as a procedural indication, lower liver volumes, and lower liver stiffness levels measured by transient elastography before treatment (P < 0.05). Multivariate logistic regression analysis identified preoperative liver stiffness level as an independent predictor of model for end-stage liver disease sodium score amelioration following balloon-occluded retrograde transvenous obliteration (P < 0.05), and receiver operating characteristic curve analysis determined a liver stiffness cutoff value of 21.6 kPa, with a sensitivity of 76.0% and specificity of 69.6%. The Kaplan-Meier method determined that overall survival rates after treatment in patients with liver stiffness < 21.6 kPa were significantly higher than in patients with liver stiffness ≥ 21.6 kPa (P < 0.05). Conclusions: Liver stiffness measured by transient elastography may predict improvements in model for end-stage liver disease sodium scores and in survival rates after portosystemic shunt occlusion in portal hypertension patients.
Introduction
Balloon-occluded retrograde transvenous obliteration (BRTO) is used in the treatment of gastric fundal varices and refractory encephalopathy associated with portosystemic shunts (PSSs). [1] [2] [3] Several studies have demonstrated that BRTO decreases collateral venous flow and increases portal blood flow, thereby improving hepatic functional reserve. [2] [3] [4] [5] In addition to the effectiveness of BRTO in treating gastric varices (GV) and hepatic encephalopathy (HE) in portal hypertension patients, obliterating major shunts can improve liver function and long-term patient outcomes. [6] [7] [8] The model for end-stage liver disease (MELD) prognostic scoring system correlates with residual hepatic function and short-term and intermediate-term mortality in cirrhotic and end-stage liver disease patients, [9] [10] [11] and unlike the Child-Pugh (CP) scoring system, it is based on objective variables rather than subjective assessments of degree of clinical abnormalities. 12 Furthermore, hyponatremia indicates hepatic decompensation in cirrhotic patients; therefore, the MELD sodium (MELD-Na) score is thought to provide more accurate prognoses than the MELD score. 13, 14 Moreover, changes in MELD-Na score over time were superior to the initial MELD-Na score at predicting the occurrence of cirrhotic complications, such as variceal bleeding and HE in advanced cirrhotic patients. 12 Some studies have demonstrated improvements in CP and MELD scores following BRTO, 5, 15 and Saad et al. reported that the MELD score might be a more sensitive gauge of hepatic synthetic function than the CP score for patients undergoing BRTO. 15 However, to the best of our knowledge, no studies have evaluated changes in MELD-Na score following major shunt occlusion for GV or HE. Hence, our study consists of two components. The first component investigated effects of BRTO on the MELD-Na score, a prognostic predictor in cirrhotic patients, and attempted identifying predictive factors of score reductions by shunt occlusion in portal hypertension patients. The second component analyzed long-term outcomes following PSS occlusion in patients using predictors of MELD-Na score amelioration post-BRTO identified by the first component.
Methods
Study design. This single-center, retrospective study examined patients' medical records, which included reviews of laboratory data and imaging findings. The research was carried out in accordance with the Declaration of Helsinki and was approved by our hospital's institutional review board (H29-095).
Patients. The study participants included cirrhotic patients who had GV or HE with a gastrorenal shunt (GRS) or a splenorenal shunt (SRS). The exclusion criteria were obstruction of the portal vein trunk and/or splenic vein, refractory ascites, and CP score ≥ 11. The biochemical, clinical, and ultrasonographic findings established a diagnosis of cirrhosis. Between February 2008 and March 2017, 84 patients with isolated GV or refractory HE underwent BRTO at our hospital. Four patients whose procedures were unsuccessful were excluded from the analysis. Ten patients who had received anticoagulants, including warfarin, were excluded from the analysis, because their prothrombin time percentage activities and prothrombin time-international normalized ratio (PT-INR) were unsuitable for CP, MELD, and MELD-Na score calculations. Finally, data of 70 patients were analyzed and followed for at least 1 month after PSS occlusion. Table 1 presents baseline clinical characteristics. All seven patients classified as CP class C had 10 CP score points, and all of them underwent BRTO for refractory HE. In other words, 3 points were assigned to them for the category of "encephalopathy" in the CP scoring system. Tumor staging (T factor) of hepatocellular carcinoma (HCC) was performed according to the Liver Cancer Study Group of Japan criteria 16 and was based on the following conditions: (i) solitary, (ii) no greater than 2 cm in diameter, and (iii) without vascular invasion. Stage I was defined as fulfilling all three conditions (T1), stage II as fulfilling two conditions (T2), stage III as fulfilling one condition (T3), stage IV-A as fulfilling none of the three conditions (T4) with no distant metastases or any T factor with lymph node metastases, and stage IV-B as fulfilling any T factor with distant metastases.
Balloon-occluded retrograde transvenous obliteration procedure. The BRTO procedure was essentially performed using the method described by Kanagawa et al., 1 and the previously described procedural protocol was followed. 17, 18 Following the insertion of an 8-Fr catheter sheath introducer (Terumo Corp., Tokyo, Japan) from the right femoral vein under local anesthesia, a 20-mm-diameter 6-Fr occlusion balloon catheter (Terumo Clinical Supply Co., Gifu, Japan) was advanced as far as possible toward the periphery of the GRS or SRS via the left renal vein using the sheath introducer. After the balloon-occluded retrograde transvenous varicerography, 5% ethanolamine oleate with iopamidol, which comprises 10% ethanolamine oleate (Oldamin; Takeda Pharmaceutical Company, Osaka, Japan) and an equal amount of iopamidol (Iopamiron; Bayer Yakuhin, Osaka, Japan), was slowly injected through the catheter until 5% of the ethanolamine oleate with iopamidol adequately stayed in the SRS in the HE cases or until the GV and the feeding veins were visualized in the GV cases. This setup remained in place until the next morning when the balloon catheter was removed after checking for the presence of a stable thrombus by injecting contrast medium on the second day.
Laboratory tests. Hepatic function markers, including bilirubin, albumin, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, ammonia, indocyanine green retention rate at 15 min, and PT-INR were evaluated before and 1 month after BRTO. In addition, complete blood count, including white blood cell count, hemoglobin concentration, and platelet count; electrolytes, namely, sodium and potassium; and renal function, comprising the blood urea nitrogen and creatinine levels, were assessed. The aspartate aminotransferase-to-platelet ratio index, fibrosis-4 index, and the MELD-Na score were calculated pre-BRTO and 1 month post-BRTO using previously published equations. 14, 19, 20 The patients were assigned to three groups based on their MELD-Na score changes post-BRTO: the "ameliorated" group comprised patients whose MELD-Na scores decreased; the "unchanged" group, those whose MELD-Na scores remained the same; and the "deteriorated" group, those whose MELD-Na scores increased.
Measurement of portal-splenic hemodynamic parameters. The wedged hepatic venous pressure was measured, and the hepatic venous pressure gradient was calculated on the first day before the shunt vessels were occluded and on the second day, immediately after checking for a stable thrombus. 17, 18 The portal flow volume (PFV) was calculated using portal flow velocity and diameter of the main portal vein that was measured by Doppler ultrasonography before and 1 month after BRTO. 4 The liver and spleen volumes were measured using axial contrast-enhanced computed tomography images at 5-mm intervals pre-BRTO and 1 month post-BRTO.
Transient elastography. Liver stiffness (LS) was measured by transient elastography (TE) using the FibroScan system (Echosens SA, Paris, France) before and 1 month after BRTO. 21 The measurements were undertaken using an M probe placed on the skin above the right intercostal space with the patient lying in the supine position. Ten successful measurements were obtained at various locations for each patient. TE procedures that obtained 10 valid measurements with success rates ≥ 60% and interquartile ranges < 30% were considered successful measurements. The median value from 10 valid measurements was considered to be the LS and expressed in kilopascals (kPa).
Statistical analyses. The statistical analyses were performed using JMP software, version 13 (SAS Institute Inc., Cary, NC, USA), and the data were expressed as means and standard deviations. The paired t-test was used for pairwise comparisons between pretreatment and posttreatment data, and unpaired t-test was used to compare two independent samples. Categorical parameters were analyzed using Fisher's exact test. To identify predictors of MELD-Na score amelioration following BRTO, univariate associations among the groups were assessed using the chi-squared test. Multivariate logistic regression analyses were performed to calculate the odds ratios, 95% confidence intervals, and P values for the different factors. Predictors of an MELD-Na score decline after PSS occlusion were assessed using receiver operating characteristic (ROC) curve analysis. The area under the ROC curve was used to evaluate the ability of a factor to predict MELD-Na score improvement post-BRTO, and the optimum cutoff value for each predictor was determined. Overall survival rates were calculated using the Kaplan-Meier method and compared using the log-rank test. Survival time was defined as the interval between dates of BRTO and of the last follow-up assessment or of liver-related or non-liver-related death, and the follow-up period ended on March 31, 2017. A P value < 0.05 was considered statistically significant.
Results
Model for end-stage liver disease sodium score changes post-balloon-occluded retrograde transvenous obliteration. Compared with the pre-BRTO MELD-Na score (10.5 ± 3.1), the MELD-Na score did not change significantly 1 month post-BRTO (10.1 ± 3.3) (P = 0.29). One month after PSS occlusion, the MELD-Na score had decreased in 31 (44.3%) patients, was unchanged in 17 (24.3%) patients, and had increased in 22 (31.4%) patients. Compared with the pre-BRTO values, the MELD-Na score component values changed 1 month post-BRTO as follows: PT-INR, 1.24 ± 0.15 to 1.19 ± 0.16 (P < 0.01); bilirubin, 1.23 ± 0.59 to 1.08 ± 0.63 mg/dL (P < 0.01); creatinine, 0.73 ± 0.25 to 0.75 ± 0.31 mg/dL (P = 0.30); and sodium, 139.2 ± 2.7 to 139.0 ± 2.8 mmol/L (P = 0.47).
Model for end-stage liver disease sodium score changes post-balloon-occluded retrograde transvenous obliteration based on preoperative clinical, biochemical, and hemodynamic parameters. The patients were divided into two groups: the ameliorated group (n = 31) and the non-ameliorated group (n = 39) that comprised patients with unchanged and increased MELD-Na scores. Table 2 presents results from the univariate analyses to find predictors of MELD-Na score reduction post-BRTO. An MELD-Na score decline after PSS occlusion was strongly associated with HE as a procedural indication (P = 0.02), lower liver volumes (P = 0.04), and lower LS levels (P = 0.01) before treatment. The multivariate logistic regression analysis identified preoperative LS levels measured using the FibroScan system as the strongest independent predictor of MELD-Na score reduction following BRTO (odds ratio 1.04; 95% confidence interval 1.01-1.09; P = 0.02) ( Table 2 ). The ROC curve analysis showed that the area under the ROC for predicting a decrease in MELD-Na score post-BRTO was 0.742 and that the optimum pre-BRTO LS cutoff value to achieve an MELD-Na score decline in response to the procedure was 21.6 kPa, with a sensitivity of 76.0% and specificity of 69.6% (Fig. S1 ).
Comparisons of patients with lower and higher pre-balloon-occluded retrograde transvenous obliteration liver stiffness levels in relation to preoperative factors. Baseline clinical characteristics were analyzed in the 48 patients in whom TE measured LS using the FibroScan system. Successful LS measurements could not be obtained from all patients, because of severe obesity or ascites in 10 patients and scheduling restrictions relating to 12 patients. No significant differences were observed in most pretreatment clinical characteristics, including age, sex, etiology of cirrhosis, hepatic functional reserve, and concomitant HCC, between the LS ≥ 21.6 kPa group and the LS < 21.6 kPa group (Table 3) . While patients of the LS ≥ 21.6 kPa group had significantly higher liver volumes than those of the LS < 21.6 kPa group pre-BRTO (P = 0.04), no significant differences were observed in preoperative wedged hepatic venous pressure and hepatic venous pressure gradient, aspartate aminotransferase-to-platelet ratio index, fibrosis-4 index, and PFV between the groups.
Comparisons of postoperative courses in patients with lower and higher pre-balloon-occluded retrograde transvenous obliteration liver stiffness levels. One month post-BRTO, the MELD-Na score had declined in 30.4%, was unchanged in 34.8%, and increased in 34.8% of patients with LS ≥ 21.6 kPa pre-BRTO, and the MELD-Na score had declined in 72.0% of patients with LS < 21.6 kPa pre-BRTO (Fig. 1a) . No significant change occurred in the MELD-Na score 1 month after PSS occlusion in the LS ≥ 21.6 kPa group. In contrast, compared with the preoperative MELD-Na score (10.4 ± 2.8), postoperative MELD-Na score (8.7 ± 3.1) was significantly lower in the LS < 21.6 kPa group (P < 0.01) (Fig. 1b) . Unlike in patients with LS ≥ 21.6 kPa pre-BRTO, the values of some MELD-Na score components improved significantly at 1 month post-BRTO in the patients with LS < 21.6 kPa pre-BRTO as follows: PT-INR, 1.21 ± 0.17 to 1.14 ± 0.16 (P < 0.01); bilirubin, 1.27 ± 0.51 to 1.01 ± 0.61 mg/dL (P < 0.01); and sodium, 139.0 ± 2.4 to 139.9 ± 2.1 mmol/L (P < 0.01) (Fig. 1c-f) , and these changes were accompanied by statistically significant increases in the PFV (875.9 ± 379.6 to 1374.6 ± 495.6 mL/min, P < 0.01), liver volume (936.3 ± 249.2 to 1012.5 ± 251.6 cm 3 , P < 0.01), and LS (13.7 ± 5.1 to 20.5 ± 11.1 kPa, P < 0.01) (Fig. 2) .
Comparisons of long-term outcomes in patients with lower and higher pre-balloon-occluded retrograde transvenous obliteration liver stiffness levels. We analyzed the complication and mortality rates post-BRTO during a median observation period of 126.5 weeks (range 9-452 weeks). The complication rates associated with secondary elevation of portal venous pressure post-BRTO, including the aggravation of esophageal varices, ascites, and pleural effusion, were markedly lower in patients with LS < 21.6 kPa than in those with LS ≥ 21.6 kPa (20.0% vs 43.5%, P = 0.07) ( Table 4 ). In addition, the mortality rates post-BRTO were significantly lower in the LS < 21.6 kPa group than in the LS ≥ 21.6 kPa group (20.0% vs 52.2%, P < 0.01) ( Table 4 ). Significant differences were observed in the survival rates post-BRTO throughout the follow-up period between the groups (P = 0.04) (Fig. 3) . Vital prognoses were more favorable for patients with LS < 21.6 kPa pre-BRTO than for those with LS ≥ 21.6 kPa pre-BRTO, and the 1-, 3-, and 5-year post-BRTO survival rates were 100.0% versus 90.4%, 80.1% versus 59.4%, and 64.7% versus 39.6%, respectively.
Discussion
Kumamoto et al. coined the term "PSS syndrome" to refer to a gradual decline in liver function reflected by CP score progression caused by the presence of large spontaneous PSSs. 6 Saad et al. further elaborated on this term by describing a complete syndrome that included clinical and imaging findings. 22 Several studies have demonstrated that BRTO protects against lowering hepatic functional reserve and worsening vital prognoses by obliterating major PSSs. [6] [7] [8] 23, 24 The long-term outcomes post-BRTO for GV are satisfactory, with survival rates of 75-76% at 3 years and 50-72% at 5 years. 7, 8, [23] [24] [25] These rates are similar to the cumulative survival rates of 91.8%, 70.3%, and 51.6% at 1, 3, and 5 years, respectively, which were determined in our study for BRTO for GV or HE. To prevent the progression of PSS syndrome, endovascular treatments like BRTO should be considered to obliterate PSSs. However, when and on whom BRTO should be performed remain unclear. This is due to the risk of portal hypertension worsening as portal hypertension deterioration and liver function improvement are opposing outcomes.
In this study, TE and the FibroScan system were used to establish the LS level, and a cutoff value of 21.6 kPa was determined as a significant and independent predictor of MELD-Na score improvements post-BRTO in portal hypertension patients. This study also demonstrated that overall survival rates in patients with LS < 21.6 kPa were significantly higher than those in patients with LS ≥ 21.6 kPa throughout the follow-up period. While some studies indicated that hepatic functional reserve, determined using CP classification, and the presence of HCC pre-BRTO were significantly associated with long-term outcomes post-BRTO in cirrhotic patients, 3, 7, 8, 25 this study showed that CP score and concomitant HCC were not significantly associated with MELD-Na score decrease post-BRTO. Hence, in addition to CP classification and presence of HCC, LS measured using TE could be another Data are presented as means and standard deviations, unless otherwise specified. P values are for comparisons between the patients with LS ≥ 21.6 kPa and those with LS < 21.6 kPa. APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4; GV, gastric varices; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HE, hepatic encephalopathy; HVPG, hepatic venous pressure gradient; LS, liver stiffness; MELD, model for end-stage liver disease; MELD-Na, model for end-stage liver disease sodium; NASH, nonalcoholic steatohepatitis; PFV, portal flow volume; WHVP, wedged hepatic venous pressure.
prognostic predictor in portal hypertension patients undergoing BRTO. Furthermore, our results suggest that LS measurement, described as a noninvasive surrogate marker of hepatic fibrosis, portal venous pressure, and hepatic functional reserve, [26] [27] [28] could reflect liver atrophy/swelling that is affected by portal inflow, particularly in cases with large PSSs pre-BRTO and post-BRTO. Figure 1 (a) Changes in the model for end-stage liver disease sodium (MELD-Na) score and in the four factors comprising the MELD-Na scoring system at 1 month post-balloon-occluded retrograde transvenous obliteration (BRTO) according to the preoperative liver stiffness (LS) value. At 1 month post-BRTO, the MELD-Na score had decreased in 30.4%, was unchanged in 34.8%, and had increased in 34.8% of the patients with higher LS levels pre-BRTO, and 72.0% of the patients with lower LS levels before treatment showed a reduction in the MELD-Na score in response to portosystemic shunt (PSS) occlusion. , ameliorated; , unchanged; , deteriorated. (b) The MELD-Na score did not change significantly at 1 month post-BRTO in the LS ≥ 21.6 kPa group. BRTO significantly reduced the MELD-Na score after the procedure in the LS < 21.6 kPa group. (c-f) PSS occlusion significantly improved the prothrombin time-international normalized ratio (PT-INR) and the bilirubin and sodium levels at 1 month post-BRTO in the patients with LS < 21.6 kPa pre-BRTO. No significant changes were observed in these components of the MELD-Na score following PSS occlusion in the patients with LS ≥ 21.6 kPa before treatment. , before; , after (1 month); NS, not significant. The data presented are the means and standard deviations. **P < 0.01 for the comparison between the groups. [Color figure can be viewed at wileyonlinelibrary.com]
Yamamoto et al. demonstrated that a lower LS level determined by TE was a predictive factor of improvements in albumin level, which is indicative of hepatic synthetic function, post-BRTO, and that the best cutoff point for the LS value was 22.9 kPa, with sensitivity and specificity of 78.4% and 69.2%, respectively, for predictions of albumin level improvements after PSS occlusion. 29 Recently, Rajakannu et al. showed that a preoperative LS value ≥ 22.0 kPa with a sensitivity of 42.9% and specificity of 92.6% Figure 3 Overall survival rates post-balloon-occluded retrograde transvenous obliteration (BRTO) during the follow-up period according to the preoperative liver stiffness (LS) value using the Kaplan-Meier method. A significant difference was found between patients with LS ≥ 21.6 kPa and those with LS < 21.6 kPa with respect to survival post-BRTO during the follow-up period (P = 0.04). The vital prognoses were more favorable in the patients with lower preoperative LS values than in those with higher preoperative LS values, and the 1-(1Y), 3-(3Y), and 5-year (5Y) survival rates post-BRTO were 100.0% versus 90.4%, 80.1% versus 59.4%, and 64.7% versus 39.6%, respectively. Figure 2 Changes in the portal flow volume (PFV), liver volume, and liver stiffness (LS) at 1 month post-balloon-occluded retrograde transvenous obliteration (BRTO) according to the preoperative LS value. BRTO resulted in statistically significant increases in the PFV, liver volume, and LS postoperatively in the patients with lower LS levels before treatment, and no significant changes were observed in these parameters post-BRTO in the patients with higher pre-BRTO LS levels. , before; , after (1 month); NS, not significant. The data presented are the means and standard deviations. *P < 0.05 for the comparison between the groups. **P < 0.01 for the comparison between the groups. [Color figure can be viewed at wileyonlinelibrary.com] EV, esophageal varices; LS, liver stiffness. *P = 0.07 compared with patients with LS ≥ 21.6 kPa. **P < 0.01 compared with patients with LS ≥ 21.6 kPa.
could predict postoperative hepatic decompensation after liver resection for HCC. 30 Surprisingly, these results are very similar to ours; therefore, a "point of no return" might exist at an LS value of around 21-23 kPa in relation to the recovery of hepatic function and extension of vital prognoses after procedures in advanced chronic liver disease patients. Here, we theorize that there may be a threshold LS value that can detect liver response or nonresponse to increased portal flow. In fact, this study shows a significant increase in liver volume in response to significant PFV increases induced by BRTO in patients with lower LS levels, but no statistically significant changes occurred in the PFV and liver volume after PSS occlusion in patients with higher LS levels. Thus, if the aforementioned threshold is verified, BRTO could be feasible for cases with "non-stiff livers" to prevent PSS syndrome progression and increase survival rates.
PSSs, including GRS and SRS, are prognostic factors for a variety of pathological conditions, including glucose intolerance and insulin resistance (IR), other than for GV formation and shunt encephalopathy. 31, 32 Previous studies suggest that hyperinsulinemia and IR contribute to deterioration of chronic liver disease by enhancing hepatic fibrogenesis and promoting hepatocarcinogenesis. [33] [34] [35] Some other reports stated that PSS occlusion improved the hyperinsulinemia associated with IR. 17, 36 Additionally, our present study revealed that, unlike in patients with LS ≥ 21.6 kPa, BRTO significantly reduced both immunoreactive insulin level (12.4 ± 8.0 to 9.7 ± 6.4 μU/mL, P = 0.04) and homeostasis model assessment of IR (3.4 ± 2.5 to 2.3 ± 1.6, P = 0.03) in the patients with LS < 21.6 kPa. Hence, the long-term outcomes of patients with lower LS levels could be prolonged post-BRTO by improving not only the hepatic function but also glucose/insulin metabolism.
To the best of our knowledge, this is the first study specifically evaluating effectiveness of LS measurements at predicting changes in MELD-Na score and long-term outcomes post-BRTO in cirrhotic patients. However, the study results should be interpreted in the context of its limitations. First, this was a retrospective study. Second, the risk of a selection bias must be considered, because only 48 (68.6%) patients underwent BRTO and TE. Third, a limited number of patients were analyzed. The LS cutoff value of 21.6 kPa could not be verified, because of the small sample size. Therefore, much larger and longer prospective studies are necessary to verify the results of this study.
In conclusion, TE provides a measure of LS that is useful for predicting MELD-Na score improvement post-BRTO, and preprocedural LS measurements are encouraged for predictions of postprocedural hepatic function and long-term outcomes in portal hypertension patients undergoing BRTO for GV or HE.
